6.Juli 2006 - Nigerias President gibt Startschuß für Verkauf von Nicosan - 500 Beiträge pro Seite
eröffnet am 06.07.06 07:49:06 von
neuester Beitrag 31.07.06 15:13:44 von
neuester Beitrag 31.07.06 15:13:44 von
Beiträge: 51
ID: 1.069.663
ID: 1.069.663
Aufrufe heute: 0
Gesamt: 97.944
Gesamt: 97.944
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 25.04.24, 13:40 | 2147 | |
| vor 1 Stunde | 717 | |
| 30.04.24, 22:31 | 442 | |
| 20.04.24, 12:11 | 372 | |
| 26.04.24, 14:53 | 348 | |
| vor 1 Stunde | 341 | |
| heute 00:07 | 292 | |
| vor 1 Stunde | 257 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 8,2900 | +4,94 | 191 | |||
| 2. | 2. | 17.901,07 | -1,26 | 162 | |||
| 3. | 3. | 2.285,71 | -2,37 | 74 | |||
| 4. | 4. | 0,9650 | +16,27 | 65 | |||
| 5. | 5. | 63,64 | +1,86 | 65 | |||
| 6. | 6. | 171,78 | -5,07 | 59 | |||
| 7. | 12. | 3,7000 | +0,54 | 28 | |||
| 8. | 8. | 13,995 | +2,72 | 27 |
Feedback
Xechem Receives Approval For Sale Of NICOSAN(TM) From Nigerian Regulatory Authorities -- NAFDAC
2006-07-05 14:26 ET - News Release
NEW BRUNSWICK, N.J. -- (Business Wire) -- July 5, 2006
Xechem International, Inc. (OTC BB: XKEM). Xechem
International announced today that its subsidiary, Xechem
Pharmaceuticals Nigeria, has received approval on July 3rd, 2006 from
Nigeria's drug regulatory authority, the National Agency for Food and
Drug Administration and Control (NAFDAC), for the marketing and sale
of NICOSAN(TM), for the prophylactic management of Sickle Cell Disease
(SCD). The approval is for an initial term of two years, which will
allow Xechem to complete confirmatory Phase III clinical trials in
Nigeria. The company faces no restrictions on its ability to market
and sell the drug in Nigeria.
President Obasanjo To Launch NICOSAN(TM) at Xechem Nigeria's
Corporate Headquarters
His Excellency, President Olusegun Obasanjo, the President and
Commander in Chief of the Federal Republic of Nigeria, is expected to
officially launch NICOSAN(TM) at a ceremony to be held on July 6th,
2006 at the headquarters of Xechem Pharmaceuticals Nigeria. A number
of other dignitaries, business leaders and governmental officials are
also scheduled to attend the launch.
According to Dr. Ramesh Pandey, the Chairman and CEO of both
Companies, NAFDAC's approval of NICOSAN(TM) represents a monumental
and historical achievement for Xechem and the great people of Nigeria.
Xechem is grateful to the many people whose tireless efforts have made
this day possible. Sickle Cell Disease is a devastating and
debilitating disease for which there has never been an effective
treatment on the market. Finally, we can say categorically that is no
longer the case. To bring this drug to market first in Nigeria, a
country with by far the largest sickle cell population in the world
and whose scientists originally developed the medicine, from
historical herbal remedies, is particularly gratifying. For sickle
cell sufferers in Nigeria, the wait is over. Soon, we hope that will
be the case for other countries of the world."
About NICOSAN(TM)
NICOSAN(TM) is an anti-sickling "Natural Herbal Drug" developed by
Nigerian scientists at the National Institute for Pharmaceutical
Research and Development (NIPRD). In clinical studies conducted under
NIPRD's auspices, the drug has shown to substantially reduce the
degree of sickling of the red blood cells of those afflicted with the
disease. While not a cure, the clinical trials have confirmed that the
large majority of patients taking NICOSAN(TM) no longer experience
sickle cell "crises" while on the medication, and even among those
whose crises are not eliminated, the number and severity of the crises
are substantially reduced.
About Sickle Cell Disease
Sickle Cell disease (SCD) is an inherited blood disorder caused by
an abnormality in the hemoglobin molecule. Patients with the disease
often produce stiff, abnormally shaped red blood cells that often do
not flow freely through the blood vessels. This can create clogs in
the vessels, which in turn cut off the flow of normal hemoglobin and
oxygen to parts of the body, and can cause severe painful attacks or
"crises", damage to various organs and shortened life spans. People
with SCD often suffer unpredictable painful crises several times a
year lasting from a few hours to a week or more. In the US, there are
approximately 80,000 patients with SCD. In Nigeria, that number is
believed to be approximately 4 million, and worldwide at least 12
million individuals are afflicted with SCD.
About Xechem
Xechem International, Inc. is a development stage
biopharmaceutical company whose focus and resources are currently
being primarily directed toward the development and commercial launch
of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the United States and
Europe), which has shown efficacy in the prophylaxis management of
Sickle Cell Disease (SCD). In addition to NICOSAN(TM) and 5-HMF,
Xechem is also working on anticancer, antiviral (including AIDS),
antifungal, antimalarial and antibacterial products from natural
sources, including microbial and marine organisms. Xechem's mission is
to bring relief to the millions of people who suffer from these
diseases. Its focus is on the development of phyto-pharmaceuticals
(Natural Herbal Drugs) and other proprietary technologies, including
those used in the treatment of orphan diseases.
Forward Looking Statements
This press release contains certain forward looking statements
within the meaning of Section 27A of the Securities Act of 1933 as
amended, and section 21E of the Securities and Exchange Act of 1934,
as amended, which are intended to be covered by safe harbors created
hereby. Such forward looking statements involve known and unknown
risks and uncertainties.
Contacts:
Xechem International, Inc.
Stephen Burg, 707-425-8855
Quelle: http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…
2006-07-05 14:26 ET - News Release
NEW BRUNSWICK, N.J. -- (Business Wire) -- July 5, 2006
Xechem International, Inc. (OTC BB: XKEM). Xechem
International announced today that its subsidiary, Xechem
Pharmaceuticals Nigeria, has received approval on July 3rd, 2006 from
Nigeria's drug regulatory authority, the National Agency for Food and
Drug Administration and Control (NAFDAC), for the marketing and sale
of NICOSAN(TM), for the prophylactic management of Sickle Cell Disease
(SCD). The approval is for an initial term of two years, which will
allow Xechem to complete confirmatory Phase III clinical trials in
Nigeria. The company faces no restrictions on its ability to market
and sell the drug in Nigeria.
President Obasanjo To Launch NICOSAN(TM) at Xechem Nigeria's
Corporate Headquarters
His Excellency, President Olusegun Obasanjo, the President and
Commander in Chief of the Federal Republic of Nigeria, is expected to
officially launch NICOSAN(TM) at a ceremony to be held on July 6th,
2006 at the headquarters of Xechem Pharmaceuticals Nigeria. A number
of other dignitaries, business leaders and governmental officials are
also scheduled to attend the launch.
According to Dr. Ramesh Pandey, the Chairman and CEO of both
Companies, NAFDAC's approval of NICOSAN(TM) represents a monumental
and historical achievement for Xechem and the great people of Nigeria.
Xechem is grateful to the many people whose tireless efforts have made
this day possible. Sickle Cell Disease is a devastating and
debilitating disease for which there has never been an effective
treatment on the market. Finally, we can say categorically that is no
longer the case. To bring this drug to market first in Nigeria, a
country with by far the largest sickle cell population in the world
and whose scientists originally developed the medicine, from
historical herbal remedies, is particularly gratifying. For sickle
cell sufferers in Nigeria, the wait is over. Soon, we hope that will
be the case for other countries of the world."
About NICOSAN(TM)
NICOSAN(TM) is an anti-sickling "Natural Herbal Drug" developed by
Nigerian scientists at the National Institute for Pharmaceutical
Research and Development (NIPRD). In clinical studies conducted under
NIPRD's auspices, the drug has shown to substantially reduce the
degree of sickling of the red blood cells of those afflicted with the
disease. While not a cure, the clinical trials have confirmed that the
large majority of patients taking NICOSAN(TM) no longer experience
sickle cell "crises" while on the medication, and even among those
whose crises are not eliminated, the number and severity of the crises
are substantially reduced.
About Sickle Cell Disease
Sickle Cell disease (SCD) is an inherited blood disorder caused by
an abnormality in the hemoglobin molecule. Patients with the disease
often produce stiff, abnormally shaped red blood cells that often do
not flow freely through the blood vessels. This can create clogs in
the vessels, which in turn cut off the flow of normal hemoglobin and
oxygen to parts of the body, and can cause severe painful attacks or
"crises", damage to various organs and shortened life spans. People
with SCD often suffer unpredictable painful crises several times a
year lasting from a few hours to a week or more. In the US, there are
approximately 80,000 patients with SCD. In Nigeria, that number is
believed to be approximately 4 million, and worldwide at least 12
million individuals are afflicted with SCD.
About Xechem
Xechem International, Inc. is a development stage
biopharmaceutical company whose focus and resources are currently
being primarily directed toward the development and commercial launch
of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the United States and
Europe), which has shown efficacy in the prophylaxis management of
Sickle Cell Disease (SCD). In addition to NICOSAN(TM) and 5-HMF,
Xechem is also working on anticancer, antiviral (including AIDS),
antifungal, antimalarial and antibacterial products from natural
sources, including microbial and marine organisms. Xechem's mission is
to bring relief to the millions of people who suffer from these
diseases. Its focus is on the development of phyto-pharmaceuticals
(Natural Herbal Drugs) and other proprietary technologies, including
those used in the treatment of orphan diseases.
Forward Looking Statements
This press release contains certain forward looking statements
within the meaning of Section 27A of the Securities Act of 1933 as
amended, and section 21E of the Securities and Exchange Act of 1934,
as amended, which are intended to be covered by safe harbors created
hereby. Such forward looking statements involve known and unknown
risks and uncertainties.
Contacts:
Xechem International, Inc.
Stephen Burg, 707-425-8855
Quelle: http://www.stockwatch.com/swnet/newsit/newsit_newsit.aspx?bi…
Was wird sich denn jetzt heute tun, deiner Meinung nach?
Antwort auf Beitrag Nr.: 22.428.640 von nomayo am 06.07.06 07:58:22das kann doch niemand vorhersagen.
Ich denke aber, daß ein offizieller Launch eines Medikaments ein Unternehmen von einem Hoffnungsträger zu einem Geldverdiener befördert.
Wenn dies mit der notwendigen Publizität passiert, dann kann das zu erheblichen Kurssteigerungen führen.
Ich denke aber, daß ein offizieller Launch eines Medikaments ein Unternehmen von einem Hoffnungsträger zu einem Geldverdiener befördert.
Wenn dies mit der notwendigen Publizität passiert, dann kann das zu erheblichen Kurssteigerungen führen.
Habt Ihr gesehen, daß erst eine halbe Stunde nach Börsenschluss noch über 2,7 Mill für 0,09 gekauft wurden ?
Trading Spotlight
Antwort auf Beitrag Nr.: 22.428.660 von as25 am 06.07.06 08:04:51oh! In USA? Hast Du dazu mal eine Quelle? (times and sales)
Antwort auf Beitrag Nr.: 22.428.660 von as25 am 06.07.06 08:04:51Das kann genausogut ein trade während des tages gewesen sein, der nachgetragen wurde. also nicht überbewerten
Orphan Drugs
The term "orphan drug" refers to a product that treats a rare disease affecting fewer than 200,000 Americans. The Orphan Drug Act was signed into law on January 4, 1983. Since the Orphan Drug Act passed, over 100 orphan drugs and biological products have been brought to market.
The intent of the Orphan Drug Act is to stimulate the research, development, and approval of products that treat rare diseases. This mission is accomplished through several mechanisms:
* Sponsors are granted seven years of marketing exclusivity after approval of its orphan drug product.
* Sponsors also are granted tax incentives for clinical research they have undertaken.
* FDA's Office of Orphan Products Development coordinates research study design assistance for sponsors of drugs for rare diseases [Notice: This link will take you outside the CDER web site].
* The Office of Orphan Products Development also encourages sponsors to conduct open protocols, allowing patients to be added to ongoing studies.
* Grant funding is available to defray costs of qualified clinical testing expenses incurred in connection with the development of orphan products.
The term "orphan drug" refers to a product that treats a rare disease affecting fewer than 200,000 Americans. The Orphan Drug Act was signed into law on January 4, 1983. Since the Orphan Drug Act passed, over 100 orphan drugs and biological products have been brought to market.
The intent of the Orphan Drug Act is to stimulate the research, development, and approval of products that treat rare diseases. This mission is accomplished through several mechanisms:
* Sponsors are granted seven years of marketing exclusivity after approval of its orphan drug product.
* Sponsors also are granted tax incentives for clinical research they have undertaken.
* FDA's Office of Orphan Products Development coordinates research study design assistance for sponsors of drugs for rare diseases [Notice: This link will take you outside the CDER web site].
* The Office of Orphan Products Development also encourages sponsors to conduct open protocols, allowing patients to be added to ongoing studies.
* Grant funding is available to defray costs of qualified clinical testing expenses incurred in connection with the development of orphan products.
Was bedeutet „Orphan Drug Status“?
„Orphan Drugs“ sind in der europäischen Gesetzgebung[2] Arzneimittel für seltene Leiden. Die EU stuft eine Erkrankungen als „selten“ ein, wenn nicht mehr als 5 von 10.000 Personen betroffen sind. Für eine Registrierung als „Orphan Drug“ gelten ganz bestimmte Voraussetzungen: So prüft die Behörde u.a. nach strengsten Kriterien, ob das Arzneimittel und dessen Wirkungsmechanismus eine effektive Behandlung der Erkrankung in Aussicht stellen.
Da der potenzielle Absatzmarkt für solche Produkte begrenzt ist, wird durch die Verordnung des Europäischen Parlaments und des Rates die Entwicklung von Arzneimitteln für seltene Leiden gezielt gefördert. Damit sind zahlreiche Vorteile verbunden, wie kostenlose Unterstützung bei der Erstellung von klinischen Prüfplänen (ansonsten kostenpflichtig in der EU), Gebührenermäßigung bzw. –befreiung sowie Exklusivität bei der Zulassung und verbesserte Chancen auf Forschungszuschüsse der EU.
„Orphan Drugs“ sind in der europäischen Gesetzgebung[2] Arzneimittel für seltene Leiden. Die EU stuft eine Erkrankungen als „selten“ ein, wenn nicht mehr als 5 von 10.000 Personen betroffen sind. Für eine Registrierung als „Orphan Drug“ gelten ganz bestimmte Voraussetzungen: So prüft die Behörde u.a. nach strengsten Kriterien, ob das Arzneimittel und dessen Wirkungsmechanismus eine effektive Behandlung der Erkrankung in Aussicht stellen.
Da der potenzielle Absatzmarkt für solche Produkte begrenzt ist, wird durch die Verordnung des Europäischen Parlaments und des Rates die Entwicklung von Arzneimitteln für seltene Leiden gezielt gefördert. Damit sind zahlreiche Vorteile verbunden, wie kostenlose Unterstützung bei der Erstellung von klinischen Prüfplänen (ansonsten kostenpflichtig in der EU), Gebührenermäßigung bzw. –befreiung sowie Exklusivität bei der Zulassung und verbesserte Chancen auf Forschungszuschüsse der EU.
Moin Moin,
kann Euch nur sagen, last Euch heute nicht raausschütteln.
Es ist doch offensichtlich das hier Lemming abfischen angesagt ist.
Der nachbörsliche Kurs wurde auf 0,091 hochgezogen mit über 2,5 Mio.
Also last Euch nicht verunsichern und haltet Eure Shares fest.
buxte
kann Euch nur sagen, last Euch heute nicht raausschütteln.
Es ist doch offensichtlich das hier Lemming abfischen angesagt ist.
Der nachbörsliche Kurs wurde auf 0,091 hochgezogen mit über 2,5 Mio.
Also last Euch nicht verunsichern und haltet Eure Shares fest.
buxte
Recent Trades - Last 10
Time Ex Price Change Volume
16:31:36 Q 0.09 +0.0015 2,786,927
16:03:25 Q 0.073 -0.0155 16,000
16:02:18 Q 0.073 -0.0155 16,000
16:01:55 Q 0.0735 -0.015 1,000
16:01:42 Q 0.073 -0.0155 41,878
16:00:44 Q 0.0755 -0.013 86,700
16:00:18 Q 0.075 -0.0135 15,000
16:00:16 Q 0.0755 -0.013 34,238
16:00:08 Q 0.076 -0.0125 25,000
16:00:06 Q 0.075 -0.0135 1,333
http://www.stockwatch.com/swnet/utilit/utilit_snapsh_result.…
Time Ex Price Change Volume
16:31:36 Q 0.09 +0.0015 2,786,927
16:03:25 Q 0.073 -0.0155 16,000
16:02:18 Q 0.073 -0.0155 16,000
16:01:55 Q 0.0735 -0.015 1,000
16:01:42 Q 0.073 -0.0155 41,878
16:00:44 Q 0.0755 -0.013 86,700
16:00:18 Q 0.075 -0.0135 15,000
16:00:16 Q 0.0755 -0.013 34,238
16:00:08 Q 0.076 -0.0125 25,000
16:00:06 Q 0.075 -0.0135 1,333
http://www.stockwatch.com/swnet/utilit/utilit_snapsh_result.…
Antwort auf Beitrag Nr.: 22.428.846 von zielony am 06.07.06 08:37:11Irgendwie mag ich es lieber, wenn der Tag mit niedrigen Kursen beginnt, und diese sich dann schön nach oben entwickeln. 
Der Kurs wird auf 0,50 zurückgehen, wie immer, die Party ist rum, da müssen schon bessere News kommen.
Antwort auf Beitrag Nr.: 22.428.877 von fjellraeven am 06.07.06 08:41:07JA ich auch, aber die Heuschrecken sind schon wo anders.
Was geblieben ist sind ängstliche Lemminge, die heute alles verkaufen werden. XKEM Zock ist vorbei!
Was geblieben ist sind ängstliche Lemminge, die heute alles verkaufen werden. XKEM Zock ist vorbei!
Die Aktie kommt von 0,005 liegt also noch fett im Plus, das wird fette Gewinnmitnahmen und Verlustbegrenzungen geben, allmächt.
Sell on good News!
Kursziel 0,02$
Antwort auf Beitrag Nr.: 22.428.939 von vform am 06.07.06 08:47:33achso.
Antwort auf Beitrag Nr.: 22.428.939 von vform am 06.07.06 08:47:33Sie kommt genau von 0,001$ !!! Gewinnmitnahmen haben die Profis am 04.06 abgeschlossen 
kann nur nochmal wiederholen:
Lass Dich nicht rausdrängeln
Nutze die niedrigen Kurse zum Nachkaufen
Am Nachmittag sehen wir andere Kurse
buxte
Lass Dich nicht rausdrängeln
Nutze die niedrigen Kurse zum Nachkaufen
Am Nachmittag sehen wir andere Kurse
buxte
Mann, was seid ihr blos für arme schweine, dass ihr euch mit schadenfreude am leben erhalten müsst.
Aber es wird anders kommen und ihr verzieht euch wieder
Aber es wird anders kommen und ihr verzieht euch wieder
Antwort auf Beitrag Nr.: 22.428.951 von Graffy am 06.07.06 08:49:20graffy, wie immer gut informiert.... Du postetest ja auch etwas von einer Marktkap von 350Mio.
War falsch.
War falsch.
Antwort auf Beitrag Nr.: 22.428.963 von buxte am 06.07.06 08:50:05SELL-IF
Candlestick Analysis
Today’s Candlestick Patterns:
Long Black Candlestick
Bearish Dark Cloud Cover
Candlestick Analysis
Today’s Candlestick Patterns:
Long Black Candlestick
Bearish Dark Cloud Cover
Antwort auf Beitrag Nr.: 22.428.892 von vform am 06.07.06 08:42:50"Der Kurs wird auf 0,50 zurückgehen, wie immer, die Party ist rum, da müssen schon bessere News kommen. "
also wenigstens über den aktuellen Kurs solltest Du Dich informieren. Zurückgehen auf 0,5 wäre ein Gewinn von fast 1000%. Nicht schlehcht.
und sag doch mal welche News eine höhere Bewertung rechtfertigen würden (aber laß den Quatsch mit Übernahme - nimm mal reine Unternehmensnews.... trau Dich)
also wenigstens über den aktuellen Kurs solltest Du Dich informieren. Zurückgehen auf 0,5 wäre ein Gewinn von fast 1000%. Nicht schlehcht.
und sag doch mal welche News eine höhere Bewertung rechtfertigen würden (aber laß den Quatsch mit Übernahme - nimm mal reine Unternehmensnews.... trau Dich)
0,50 ich korrigiere auf 0,005, Du hast Recht!!!
Berlin
BID 0,055
ASK 0,069
Spread 25,45%
buxte
BID 0,055
ASK 0,069
Spread 25,45%
buxte
Berlin
Bid 10 k zu 0,055
Ask 10 k zu 0,064
Letzter 0,056 ohne Volumen
interessant, nächste Order im ASK
3,900 zu 0,150
10 k zu 0,205
buxte
Bid 10 k zu 0,055
Ask 10 k zu 0,064
Letzter 0,056 ohne Volumen
interessant, nächste Order im ASK
3,900 zu 0,150
10 k zu 0,205
buxte
Antwort auf Beitrag Nr.: 22.429.028 von vform am 06.07.06 08:56:53und nach dieser beliebigen Einfügung von Nullen - noch die zweite Frage: welche News würden denn eine Höherbewertung rechtfertigen?
und?
Hat Obasanjo schon verkündet?
Hat Obasanjo schon verkündet?
So stand es am 5.7. im business newswire:
"His Excellency, President Olusegun Obasanjo, the President and
Commander in Chief of the Federal Republic of Nigeria, is expected to
officially launch NICOSAN(TM) at a ceremony to be held on July 6th,
2006 at the headquarters of Xechem Pharmaceuticals Nigeria. A number
of other dignitaries, business leaders and governmental officials are
also scheduled to attend the launch.
"
und?
hat er verkündet?
"His Excellency, President Olusegun Obasanjo, the President and
Commander in Chief of the Federal Republic of Nigeria, is expected to
officially launch NICOSAN(TM) at a ceremony to be held on July 6th,
2006 at the headquarters of Xechem Pharmaceuticals Nigeria. A number
of other dignitaries, business leaders and governmental officials are
also scheduled to attend the launch.
"
und?
hat er verkündet?
Antwort auf Beitrag Nr.: 22.443.970 von physik am 07.07.06 06:33:17..glaubst du der stellt sich den Wecker um 5 Uhr und verkündet um 6 ??
Also, so eine Veranstaltung findet in der Regel am frühen Nachmittag statt...
Also, so eine Veranstaltung findet in der Regel am frühen Nachmittag statt...
Antwort auf Beitrag Nr.: 22.444.322 von xvs am 07.07.06 08:29:06ja, das war wohl der Grund für die fehlenden Nachrichten. Jetzt ist es bestätigt:
http://nigeria.andnetwork.com/index;jsessionid=90CD35ABFF861…
"Obasanjo commission sickle cell drug factory in Nigeria
...
an anti-sickling drug, has been comissioned by President Olusegun Obsanjo."
http://nigeria.andnetwork.com/index;jsessionid=90CD35ABFF861…
"Obasanjo commission sickle cell drug factory in Nigeria
...
an anti-sickling drug, has been comissioned by President Olusegun Obsanjo."
der vollständige Text der News
"Obasanjo commission sickle cell drug factory in Nigeria
July 7, 2006, 3 hours, 10 minutes and 26 seconds ago.
By ANDnetwork .com
A local factory that will immediately commence the production of NICOSAN - an anti-sickling drug, has been comissioned by President Olusegun Obsanjo.
Ayodele Coker, Director General of SHESTCO who disclosed this explained that NICONSAN is a drug first developed by the National Institute for Pharmaceutical Research and Development (NIPRD) for the management of sickle cell disease.
He said that NICOSAN consists of a mixture of extracts from four tropical plants, some of which are cultivated and found in the wild both within and outside Nigeria. Coker stressed that all necessary precautions had been taken to ensure safety of the products as well as continuity in the production.
According to him, the Gamma irradiation facility is to be used for food preservation, sterilisation of pharmaceutical and medical devices, as well as polymerisation and other industrial applications.
Cker said that "the drug, to be used in the treatment of sickle cell diseases, is being produced by a pharmaceutical company-Xechem-Nigeria and has been tested locally and international at Philadelphia Children’s Hospital in the United States."
The drug, which Coker said has been approved by the National Agency for Food and Drug Administration and Control (Nafdac), is also been recognised by the World Health Organisation (WHO) for the treatment of sickle cell diseases .
Coker explained that the Gamma irradiation facility is for food security and preservation of agricultural products which will cut down the loss from waste of harvested crops experienced annually stressing "more than 55% of our harvested crops are wasted thus the need for the facility and we want to cut down on this loss".
"We are confident this will help in the reduction of prices of foodstuffs all year round. With the Gamma irradiation facility, you can delay the ripening period, retain freshness and admittance of exported agriculture products in the markets. Products that go through the facility will be 100% safe for human consumption as there is no room for error.
Business Day - Nigeria"
"Obasanjo commission sickle cell drug factory in Nigeria
July 7, 2006, 3 hours, 10 minutes and 26 seconds ago.
By ANDnetwork .com
A local factory that will immediately commence the production of NICOSAN - an anti-sickling drug, has been comissioned by President Olusegun Obsanjo.
Ayodele Coker, Director General of SHESTCO who disclosed this explained that NICONSAN is a drug first developed by the National Institute for Pharmaceutical Research and Development (NIPRD) for the management of sickle cell disease.
He said that NICOSAN consists of a mixture of extracts from four tropical plants, some of which are cultivated and found in the wild both within and outside Nigeria. Coker stressed that all necessary precautions had been taken to ensure safety of the products as well as continuity in the production.
According to him, the Gamma irradiation facility is to be used for food preservation, sterilisation of pharmaceutical and medical devices, as well as polymerisation and other industrial applications.
Cker said that "the drug, to be used in the treatment of sickle cell diseases, is being produced by a pharmaceutical company-Xechem-Nigeria and has been tested locally and international at Philadelphia Children’s Hospital in the United States."
The drug, which Coker said has been approved by the National Agency for Food and Drug Administration and Control (Nafdac), is also been recognised by the World Health Organisation (WHO) for the treatment of sickle cell diseases .
Coker explained that the Gamma irradiation facility is for food security and preservation of agricultural products which will cut down the loss from waste of harvested crops experienced annually stressing "more than 55% of our harvested crops are wasted thus the need for the facility and we want to cut down on this loss".
"We are confident this will help in the reduction of prices of foodstuffs all year round. With the Gamma irradiation facility, you can delay the ripening period, retain freshness and admittance of exported agriculture products in the markets. Products that go through the facility will be 100% safe for human consumption as there is no room for error.
Business Day - Nigeria"
Nigeria Export Import Bank (NEXIM) has concluded plans to raise its share capital from N50 billion to N100 billion. This is coming at a time when President Olusegun Obasanjo gave the management and board of the bank, a part on the back for a job well done. The bank recently concluded a deal to fund a drug, NICOSAN, which would generate a yearly minimum of $5 million in foreign exchange in the first two years of operations from royalty payments and exports
Ergebnis der Umrechnung 07.07.2006
1,00 Euro € = Wechselkurs = 164,21 Nigerianische Naira
Ergebnis der Umrechnung 07.07.2006
1,00 Euro € = Wechselkurs = 164,21 Nigerianische Naira
Zu der Zahl der Betroffenen habe ich eine Frage an Euch. Wie vielen Menschen kann mit Nicosan eine kostengünstige Heilung der Sichelzellenkrankheit in Aussicht gestellt werden?
Sickle Cell Disease is found to be on the scale of front row serious killer ailments such as cancer and HIV/AIDS. Most sickler s, especially in most African communities, shy away from public exposure. Currently, between 14 million and 16 million people are said to be suffering from the disease worldwide. Out of this number, 10 million are in Africa, which includes the four million in Nigeria. Sickle Cell Disease, according to scientific research, is a genetic blood disorder caused by a point mutation on the globin chain of the haemoglobin molecule.
Sickle Cell Disease is found to be on the scale of front row serious killer ailments such as cancer and HIV/AIDS. Most sickler s, especially in most African communities, shy away from public exposure. Currently, between 14 million and 16 million people are said to be suffering from the disease worldwide. Out of this number, 10 million are in Africa, which includes the four million in Nigeria. Sickle Cell Disease, according to scientific research, is a genetic blood disorder caused by a point mutation on the globin chain of the haemoglobin molecule.
Antwort auf Beitrag Nr.: 22.606.142 von divenocke am 15.07.06 17:51:14...sorry, Link vergessen
Nigeria: Nigerian Scientists Claim Cure for Sickle Cell
Daily Trust (Abuja)
July 5, 2006
Posted to the web July 6, 2006
http://allafrica.com/stories/200607060165.html
Nigeria: Nigerian Scientists Claim Cure for Sickle Cell
Daily Trust (Abuja)
July 5, 2006
Posted to the web July 6, 2006
http://allafrica.com/stories/200607060165.html
Antwort auf Beitrag Nr.: 22.606.142 von divenocke am 15.07.06 17:51:14Eine Angabe von 12.000.000 betroffenen Menschen.
Nigerian President Olusegun Obasanjo Launches Xechem's Sickle Cell Drug, NICOSAN(TM), in Nigeria
Story Date: 2006-Jul-11 at 06:30:03
http://news.pajamasmedia.com/politics/2006/07/11/9558733_Nig…
In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, and worldwide at least 12 million individuals are afflicted with SCD.
Nigerian President Olusegun Obasanjo Launches Xechem's Sickle Cell Drug, NICOSAN(TM), in Nigeria
Story Date: 2006-Jul-11 at 06:30:03
http://news.pajamasmedia.com/politics/2006/07/11/9558733_Nig…
In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, and worldwide at least 12 million individuals are afflicted with SCD.
Antwort auf Beitrag Nr.: 22.606.142 von divenocke am 15.07.06 17:51:14Eine konservative Umsatzprognose oder Blauäugigkeit?
Allein in Nigeria 4.000.000 Betroffene.
20,-USD Monat ergibt 240,-USD pro Nase/Jahr
4.000.000 zu behandelnde Patienten in Nigeria ergibt 960.000.000,-USD
Die geschätzten Angaben zur Anzahl der erkrankten Menschen schwankt zwischen 12 und 16 Millionen.
Geschätzter Umsatz ergibt sich auch unter der Annahme, dass 4 Millionen Menschen weltweit mit dem Medikament behandelt werden.
Allein in Nigeria 4.000.000 Betroffene.
20,-USD Monat ergibt 240,-USD pro Nase/Jahr
4.000.000 zu behandelnde Patienten in Nigeria ergibt 960.000.000,-USD
Die geschätzten Angaben zur Anzahl der erkrankten Menschen schwankt zwischen 12 und 16 Millionen.
Geschätzter Umsatz ergibt sich auch unter der Annahme, dass 4 Millionen Menschen weltweit mit dem Medikament behandelt werden.
Antwort auf Beitrag Nr.: 22.607.021 von divenocke am 15.07.06 19:22:40Es wäre wohl sinnvoller, du würdest deine Beiträge im Hauptthread "Xechem - Nicosan genehmigt - Produktionsbeginn" einstellen. Wird dort von viel mehr Usern gelesen.
Antwort auf Beitrag Nr.: 22.607.447 von fjellraeven am 15.07.06 20:00:20Blödsinn...richtig Interessierte lesen alle Threads.
Antwort auf Beitrag Nr.: 22.607.447 von fjellraeven am 15.07.06 20:00:20Woher weiss ich, wo im Forum ein Hauptthread ist?
Bin ich in einem Nebenthread?
"Nigerias President gibt Startschuß für Verkauf von Nicosan"
Verkauf an wen, in welcher Menge, für wieviel und was bleibt an Gewinn hängen?
divenockeverwirrtiss
Bin ich in einem Nebenthread?
"Nigerias President gibt Startschuß für Verkauf von Nicosan"
Verkauf an wen, in welcher Menge, für wieviel und was bleibt an Gewinn hängen?
divenockeverwirrtiss
Irgendwo hab ich von einem Vorschlag für den Nobelpreis gelesen.
Hier die Quelle mit sinnvollen Zusammenhang.
Die Entwickler des Medikaments zur Bekämpfung der Sichelzellenkrankheit verdienen nationale Ehre, und, wer weiß, ein Nobelpreis kann folgen.
Friday 14th July, 2006
Hope for sickle cell patients
BABIES are blameless. But some babies, though clearly innocent, are given the death penalty. They are seen as foetal felons and their time on death row begins as soon as they are born. Many of them, when their minds free themselves from the morning mist of infancy and reach the warm climate of cognition, wish they were never born.
THEIR world is not kaleidoscopic, is compressed into that of red-hot pain. Unlike some murderers and rapists on death row, they have no remission, no reprieve. Their torment is not spent like a hurricane, the hurt hurtles on, clearing all herbal hurdles.
A sickle cell patient, puny though he is, has to contend with many vicious attackers. He is prone to stroke, kidney damage and an exceedingly painful condition in men called priapism. Sickle cell disease should own the patent for Viagra, though its cure for impotence impales men on a staff of suffering.
THE cause of sickle cell disease has been known for decades. It is caused by an errant gene. The gene is very well known, has long been caught in the searchlight of science. So why has it not been crushed like a rabbit confused and immobilised by a car’s headlamps?
THE disease is partial to blacks. This is supposed to be because they live in an area where malaria is endemic. This does not explain why African-Americans, far more than other races in the United States, are afflicted with the disease. Or why Italians – the word “malaria” comes from the Italian “mal’aria”, meaning “bad air” – are not swamped with the disease.
IT has been said the big pharmaceutical companies in the West are not ready to spend good money funding a cure for sickle cell disease because the sufferers are mostly blacks and too poor to afford the drugs. There may be some truth in this, as manufacturers of HIV drugs had to be shamed into allowing cheaper copies of their drugs to be made.
SO sickle cell patients continued to experience crises of pulverising pain and then the final crisis, which came as comfort.
UNTIL now. Now, there is real comfort. It is the comfort of life and not the relief of death, of freedom from infernal pain. A cure has been found for sickle cell disease and the breakthrough was made by Nigerians. The Minister of Science and Technology, Professor Turner Isoun, disclosed this at a news conference on Tuesday, July 4.
THIS significant news was not reported by many newspapers and those that did buried it in their inside pages. Were they erring on the side of caution? Did they smell another Abalaka vaccine controversy?
THE minister said serious research by scientists at the National Institute for Pharmaceutical Research led to the discovery. The drug, called Nicosan, was then manufactured by a pharmaceutical company in Nigeria, Xechem Pharmaceuticals Nigeria Ltd.
THE drug is said to be a potent cure for the disease. The World Health Organisation (WHO), according to the minister, had pronounced the drug the world’s most effective in the treatment of sickle cell disease. The drug has also been certified safe and succouring by the demanding Food and Drug Administration of the United States and regulatory agencies in Europe. A Congressman, Sharon Beasley-Teague, was present at the minister’s news conference and praised the Nigerian scientists who discovered the drug.
THE discovery of a cure for sickle cell disease by Nigerian scientists and the manufacture of the drug by a pharmaceutical company in Nigeria are, indeed, uncommon achievements. The discovery is as important as finding a cure for AIDS. Sickle cell disease brings misery to millions of people around the world. And like AIDS, it weakens immune system and death results.
NIGERIA, with the discovery and manufacture of the sickle cell disease drug, has taken a great step for humanity. Sickle cell patients can now expect to live a normal life. Most of them died before they were 50; some of them, with the blessing of their creator, may now live to a ripe old age.
FOUR million Nigerians are said to suffer from sickle cell disease. Though there is now a cure for the disease, everything should be done not to add to the number of sufferers. The disease is very easy to prevent. All it takes is to know one’s genotype. A person whose genotype is AS should not make babies with anybody with an identical genotype. If they do, their individual single gene AS will combine to form two sickle cell genes – sickle cell disease – in their baby.
THE problem in Nigeria is that many people do not have information on genotype screening. They live in ignorant bliss but anguish comes to stay when they have a child with sickle cell disease. There is a sickle cell support group in Nigeria but it appears it does not have much money to engage in a sustained awareness campaign. It is usually heard of during its annual meeting.
THE government and the private sector should be involved in providing information about the disease. In the United States, many newly born babies are automatically screened for the disease. The same thing should begin to happen in government hospitals in Nigeria. Children and adults should be given access to subsidised screening, if not totally free. The government can afford it. Reagents do not cost the earth.
THE discoverers of the sickle cell disease drug deserve national honour. And, who knows, a Nobel Prize may follow.
Hier die Quelle mit sinnvollen Zusammenhang.
Die Entwickler des Medikaments zur Bekämpfung der Sichelzellenkrankheit verdienen nationale Ehre, und, wer weiß, ein Nobelpreis kann folgen.
Friday 14th July, 2006
Hope for sickle cell patients
BABIES are blameless. But some babies, though clearly innocent, are given the death penalty. They are seen as foetal felons and their time on death row begins as soon as they are born. Many of them, when their minds free themselves from the morning mist of infancy and reach the warm climate of cognition, wish they were never born.
THEIR world is not kaleidoscopic, is compressed into that of red-hot pain. Unlike some murderers and rapists on death row, they have no remission, no reprieve. Their torment is not spent like a hurricane, the hurt hurtles on, clearing all herbal hurdles.
A sickle cell patient, puny though he is, has to contend with many vicious attackers. He is prone to stroke, kidney damage and an exceedingly painful condition in men called priapism. Sickle cell disease should own the patent for Viagra, though its cure for impotence impales men on a staff of suffering.
THE cause of sickle cell disease has been known for decades. It is caused by an errant gene. The gene is very well known, has long been caught in the searchlight of science. So why has it not been crushed like a rabbit confused and immobilised by a car’s headlamps?
THE disease is partial to blacks. This is supposed to be because they live in an area where malaria is endemic. This does not explain why African-Americans, far more than other races in the United States, are afflicted with the disease. Or why Italians – the word “malaria” comes from the Italian “mal’aria”, meaning “bad air” – are not swamped with the disease.
IT has been said the big pharmaceutical companies in the West are not ready to spend good money funding a cure for sickle cell disease because the sufferers are mostly blacks and too poor to afford the drugs. There may be some truth in this, as manufacturers of HIV drugs had to be shamed into allowing cheaper copies of their drugs to be made.
SO sickle cell patients continued to experience crises of pulverising pain and then the final crisis, which came as comfort.
UNTIL now. Now, there is real comfort. It is the comfort of life and not the relief of death, of freedom from infernal pain. A cure has been found for sickle cell disease and the breakthrough was made by Nigerians. The Minister of Science and Technology, Professor Turner Isoun, disclosed this at a news conference on Tuesday, July 4.
THIS significant news was not reported by many newspapers and those that did buried it in their inside pages. Were they erring on the side of caution? Did they smell another Abalaka vaccine controversy?
THE minister said serious research by scientists at the National Institute for Pharmaceutical Research led to the discovery. The drug, called Nicosan, was then manufactured by a pharmaceutical company in Nigeria, Xechem Pharmaceuticals Nigeria Ltd.
THE drug is said to be a potent cure for the disease. The World Health Organisation (WHO), according to the minister, had pronounced the drug the world’s most effective in the treatment of sickle cell disease. The drug has also been certified safe and succouring by the demanding Food and Drug Administration of the United States and regulatory agencies in Europe. A Congressman, Sharon Beasley-Teague, was present at the minister’s news conference and praised the Nigerian scientists who discovered the drug.
THE discovery of a cure for sickle cell disease by Nigerian scientists and the manufacture of the drug by a pharmaceutical company in Nigeria are, indeed, uncommon achievements. The discovery is as important as finding a cure for AIDS. Sickle cell disease brings misery to millions of people around the world. And like AIDS, it weakens immune system and death results.
NIGERIA, with the discovery and manufacture of the sickle cell disease drug, has taken a great step for humanity. Sickle cell patients can now expect to live a normal life. Most of them died before they were 50; some of them, with the blessing of their creator, may now live to a ripe old age.
FOUR million Nigerians are said to suffer from sickle cell disease. Though there is now a cure for the disease, everything should be done not to add to the number of sufferers. The disease is very easy to prevent. All it takes is to know one’s genotype. A person whose genotype is AS should not make babies with anybody with an identical genotype. If they do, their individual single gene AS will combine to form two sickle cell genes – sickle cell disease – in their baby.
THE problem in Nigeria is that many people do not have information on genotype screening. They live in ignorant bliss but anguish comes to stay when they have a child with sickle cell disease. There is a sickle cell support group in Nigeria but it appears it does not have much money to engage in a sustained awareness campaign. It is usually heard of during its annual meeting.
THE government and the private sector should be involved in providing information about the disease. In the United States, many newly born babies are automatically screened for the disease. The same thing should begin to happen in government hospitals in Nigeria. Children and adults should be given access to subsidised screening, if not totally free. The government can afford it. Reagents do not cost the earth.
THE discoverers of the sickle cell disease drug deserve national honour. And, who knows, a Nobel Prize may follow.
Saturday, July 15, 2006
NEXIM to raise share capital to N100b From Nduka Chiejina, Abuja
Nigeria Export Import Bank (NEXIM) has concluded plans to raise its share capital from N50 billion to N100 billion.
This is coming at a time when President Olusegun Obasanjo gave the management and board of the bank, a part on the back for a job well done.
The bank recently concluded a deal to fund a drug, NICOSAN, which would generate a yearly minimum of $5 million in foreign exchange in the first two years of operations from royalty payments and exports.
Antwort auf Beitrag Nr.: 22.610.033 von divenocke am 15.07.06 23:39:04Hallo, zu deiner Frage von gestern, welches denn der Hauptthread sei: Die meisten User haben sich vor einigen Tagen auf diesen - Xechem - Nicosan genehmigt - Produktionsbeginn - geeinigt, um die Infos zu konzentrieren und hierdurch die Recherche bzw. das gelegentlich notwendige Nachschlagen/Zurückblättern zu erleichtern. Die anderen Threads, bis auf den Chartthread hatten zuletzt kaum noch Beiträge, wie man am jeweiligen Datum erkennen kann.
Bis zum Produktionsbeginn war "XKEM Biotech kurz vor Produkteinführung" der Hauptthread (siehe Anzahl der Beiträge). Sein Titel machte keinen weiteren Sinn.
Du kannst jedoch selbstverständlich deine Beiträge in jedem Thread veröffentlichen oder auch einen eigenen eröffnen. Derzeit halte ich persönlich eine Konzentration für effektiver.
Bis zum Produktionsbeginn war "XKEM Biotech kurz vor Produkteinführung" der Hauptthread (siehe Anzahl der Beiträge). Sein Titel machte keinen weiteren Sinn.
Du kannst jedoch selbstverständlich deine Beiträge in jedem Thread veröffentlichen oder auch einen eigenen eröffnen. Derzeit halte ich persönlich eine Konzentration für effektiver.
Antwort auf Beitrag Nr.: 22.613.003 von divenocke am 16.07.06 04:33:10Ich fände es sehr wichtig, dass du diese News auch im Hauptthread einstellst. Danke! 
Antwort auf Beitrag Nr.: 22.609.285 von weinicht am 15.07.06 22:22:43Kommentar, siehe meinen vorletzten Beitrag! Auch ich lese in anderen Threads , aber es ist mühsamer. 
, aber es ist mühsamer. 
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
nur ein test! versuche mal ein bild zu posten!
wens stört: sorry dafür! bin extra in einem alten thread
wens stört: sorry dafür! bin extra in einem alten thread
Antwort auf Beitrag Nr.: 23.255.135 von Mahenscho am 31.07.06 15:12:06hey hat geklappt!!
das bild hat sonst keinen sinn! war nur ein test
das bild hat sonst keinen sinn! war nur ein test
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 191 | ||
| 162 | ||
| 74 | ||
| 65 | ||
| 65 | ||
| 59 | ||
| 28 | ||
| 27 | ||
| 26 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 22 | ||
| 21 | ||
| 20 | ||
| 19 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 16 | ||
| 15 | ||
| 15 |
